{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:42:19Z","timestamp":1761896539397},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,5,11]],"date-time":"2017-05-11T00:00:00Z","timestamp":1494460800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s40259-017-0219-4","type":"journal-article","created":{"date-parts":[[2017,5,11]],"date-time":"2017-05-11T15:22:24Z","timestamp":1494516144000},"page":"223-237","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents"],"prefix":"10.1007","volume":"31","author":[{"given":"Walter","family":"Reinisch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f8rgen","family":"Jahnsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juli\u00e1n","family":"Pan\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Balsa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JiSoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jee Un","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dae Hyun","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,5,11]]},"reference":[{"issue":"1","key":"219_CR1","doi-asserted-by":"crossref","first-page":"e30275","DOI":"10.1371\/journal.pone.0030275","volume":"7","author":"KJ Aaltonen","year":"2012","unstructured":"Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordstrom DC, Blom M. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One. 2012;7(1):e30275.","journal-title":"PLoS One"},{"issue":"9","key":"219_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta20090","volume":"20","author":"M Corbett","year":"2016","unstructured":"Corbett M, Soares M, Jhuti G, Rice S, Spackman E, Sideris E, et al. Tumour necrosis factor-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation. Health Technol Assess. 2016;20(9):1\u2013334.","journal-title":"Health Technol Assess"},{"issue":"4","key":"219_CR3","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/ajg.2011.73","volume":"106","author":"AC Ford","year":"2011","unstructured":"Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):644\u201359.","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"219_CR4","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00296-014-3006-2","volume":"34","author":"LL Lemos","year":"2014","unstructured":"Lemos LL, de Oliveira Costa J, Almeida AM, Junior HO, Barbosa MM, Kakehasi AM, et al. Treatment of psoriatic arthritis with anti-TNF agents: a systematic review and meta-analysis of efficacy, effectiveness and safety. Rheumatol Int. 2014;34(10):1345\u201360.","journal-title":"Rheumatol Int"},{"issue":"4","key":"219_CR5","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40259-015-0134-5","volume":"29","author":"SS Thomas","year":"2015","unstructured":"Thomas SS, Borazan N, Barroso N, Duan L, Taroumian S, Kretzmann B, et al. Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. A systematic review and meta-analysis. BioDrugs. 2015;29(4):241\u201358.","journal-title":"BioDrugs."},{"issue":"1","key":"219_CR6","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/annrheumdis-2014-206237","volume":"74","author":"KA Schie van","year":"2015","unstructured":"van Schie KA, Hart MH, de Groot ER, Kruithof S, Aarden LA, Wolbink GJ, et al. The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. Ann Rheum Dis. 2015;74(1):311\u20134.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"219_CR7","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.2217\/imt.12.114","volume":"4","author":"K Bendtzen","year":"2012","unstructured":"Bendtzen K. Anti-TNF-\u03b1 biotherapies: perspectives for evidence-based personalized medicine. Immunotherapy. 2012;4(11):1167\u201379.","journal-title":"Immunotherapy."},{"issue":"15","key":"219_CR8","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1001\/jamainternmed.2013.7430","volume":"173","author":"JR Maneiro","year":"2013","unstructured":"Maneiro JR, Salgado E, Gomez-Reino JJ. Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated inflammatory conditions: systematic review and meta-analysis. JAMA Intern Med. 2013;173(15):1416\u201328.","journal-title":"JAMA Intern Med."},{"issue":"12","key":"219_CR9","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1136\/annrheumdis-2012-202220","volume":"72","author":"S Garces","year":"2013","unstructured":"Garces S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis. 2013;72(12):1947\u201355.","journal-title":"Ann Rheum Dis"},{"key":"219_CR10","unstructured":"European Medicines Agency. Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins (draft). 2015. \n                        http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2015\/10\/WC500194507.pdf\n                        \n                    . Accessed 21 Mar 2017."},{"key":"219_CR11","unstructured":"US Food and Drug Administration. Assay development and validation for immunogenicity testing of therapeutic protein products. Guidance for industry. 2016. \n                        http:\/\/www.fda.gov\/downloads\/Drugs\/\u2026\/Guidances\/UCM192750.pdf\n                        \n                    . Accessed 21 Mar 2017."},{"key":"219_CR12","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 2014. \n                        http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2015\/01\/WC500180219.pdf\n                        \n                    . Accessed 21 Mar 2017."},{"key":"219_CR13","unstructured":"US Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for industry. 2015. \n                        http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm291128.pdf\n                        \n                    . Accessed 21 Mar 2017."},{"issue":"3","key":"219_CR14","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40259-016-0174-5","volume":"30","author":"C Pineda","year":"2016","unstructured":"Pineda C, Castaneda Hernandez G, Jacobs IA, Alvarez DF, Carini C. Assessing the immunogenicity of biopharmaceuticals. BioDrugs. 2016;30(3):195\u2013206.","journal-title":"BioDrugs."},{"issue":"10","key":"219_CR15","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","volume":"72","author":"W Park","year":"2013","unstructured":"Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72(10):1605\u201312.","journal-title":"Ann Rheum Dis"},{"key":"219_CR16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13075-016-0930-4","volume":"18","author":"W Park","year":"2016","unstructured":"Park W, Yoo DH, Jaworski J, Brzezicki J, Gnylorybov A, Kadinov V, et al. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. Arthritis Res Ther. 2016;18:25.","journal-title":"Arthritis Res Ther."},{"issue":"10","key":"219_CR17","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","volume":"72","author":"DH Yoo","year":"2013","unstructured":"Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72(10):1613\u201320.","journal-title":"Ann Rheum Dis"},{"key":"219_CR18","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13075-016-0981-6","volume":"18","author":"DH Yoo","year":"2016","unstructured":"Yoo DH, Racewicz A, Brzezicki J, Yatsyshyn R, Arteaga ET, Baranauskaite A, et al. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. Arthritis Res Ther. 2016;18:82.","journal-title":"Arthritis Res Ther."},{"key":"219_CR19","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/annrheumdis-2015-208783","volume":"76","author":"W Park","year":"2017","unstructured":"Park W, Yoo DH, Miranda P, Brzosko M, Wiland P, Gutierrez-Urena S, et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis. 2017;76:346\u201354.","journal-title":"Ann Rheum Dis"},{"key":"219_CR20","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/annrheumdis-2015-208786","volume":"76","author":"DH Yoo","year":"2017","unstructured":"Yoo DH, Prodanovic N, Jaworski J, Miranda P, Ramiterre E, Lanzon A, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis. 2017;76:355\u201363.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"219_CR21","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jpba.2008.09.020","volume":"48","author":"G Shankar","year":"2008","unstructured":"Shankar G, Devanarayan V, Amaravadi L, Barrett YC, Bowsher R, Finco-Kent D, et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal. 2008;48(5):1267\u201381.","journal-title":"J Pharm Biomed Anal"},{"issue":"4","key":"219_CR22","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S Linden van der","year":"1984","unstructured":"van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27(4):361\u20138.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"219_CR23","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315\u201324.","journal-title":"Arthritis Rheum"},{"issue":"Suppl 1","key":"219_CR24","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1586\/1744666X.2015.1090312","volume":"11","author":"JS Kim","year":"2015","unstructured":"Kim JS, Kim SH, Kwon B, Hong S. Comparison of immunogenicity test methods used in clinical studies of infliximab and its biosimilar (CT-P13). Expert Rev Clin Immunol. 2015;11(Suppl 1):S33\u201341.","journal-title":"Expert Rev Clin Immunol."},{"key":"219_CR25","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/annrheumdis-2015-208684","volume":"75","author":"MB Ruiz-Arg\u00fcello","year":"2016","unstructured":"Ruiz-Arg\u00fcello MB, Maguregui A, Ruiz del Agua A, Pascual-Salcedo D, Mart\u00ednez-Feito A, Jurado T, et al. Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars. Ann Rheum Dis. 2016;75:1693\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"219_CR26","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1097\/MIB.0000000000000709","volume":"22","author":"A Gils","year":"2016","unstructured":"Gils A, Van Stappen T, Dreesen E, Storme R, Vermeire S, Declerck PJ. Harmonization of infliximab and anti-infliximab assays facilitates the comparison between originators and biosimilars in clinical samples. Inflamm Bowel Dis. 2016;22(4):969\u201375.","journal-title":"Inflamm Bowel Dis"},{"issue":"7","key":"219_CR27","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/gutjnl-2015-309290","volume":"65","author":"S Ben-Horin","year":"2016","unstructured":"Ben-Horin S, Yavzori M, Benhar I, Fudim E, Picard O, Ungar B, et al. Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima. Gut. 2016;65(7):1132\u20138.","journal-title":"Gut"},{"issue":"2","key":"219_CR28","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1365-3083.1989.tb01204.x","volume":"30","author":"A Fomsgaard","year":"1989","unstructured":"Fomsgaard A, Svenson M, Bendtzen K. Auto-antibodies to tumour necrosis factor alpha in healthy humans and patients with inflammatory diseases and gram-negative bacterial infections. Scand J Immunol. 1989;30(2):219\u201323.","journal-title":"Scand J Immunol"},{"issue":"10","key":"219_CR29","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1016\/j.febslet.2007.04.029","volume":"581","author":"M Watanabe","year":"2007","unstructured":"Watanabe M, Uchida K, Nakagaki K, Kanazawa H, Trapnell BC, Hoshino Y, et al. Anti-cytokine autoantibodies are ubiquitous in healthy individuals. FEBS Lett. 2007;581(10):2017\u201321.","journal-title":"FEBS Lett"},{"key":"219_CR30","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1136\/annrheumdis-2016-209540","volume":"76","author":"DH Yoo","year":"2017","unstructured":"Yoo DH, Suh C-H, Shim SC, Jeka S, Cons-Molina FF, Hrycaj P, et al. A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2017;76:566\u201370.","journal-title":"Ann Rheum Dis"},{"key":"219_CR31","unstructured":"CELLTRION. CT-P13 (infliximab). FDA advisory committee briefing document. 2016. \n                        http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/ArthritisAdvisoryCommittee\/UCM484860.pdf\n                        \n                    . Accessed 21 Mar 2017."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40259-017-0219-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-017-0219-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-017-0219-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,24]],"date-time":"2017-05-24T06:28:17Z","timestamp":1495607297000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40259-017-0219-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,11]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["219"],"URL":"https:\/\/doi.org\/10.1007\/s40259-017-0219-4","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,11]]}}}